Press releaseGlobe Newswire
Nuvectis Pharma
NVCT · NASDAQ
$20.59+$1.65 (+8.71%)TodayMarket closed ·
Prev close $18.94
Latest news
- Press releaseGlobe Newswire
Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights
- Press releaseGlobe Newswire
Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
- Press releaseGlobe Newswire
Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
- NewsAvi Kapoor
Ryanair Posts Weak Q1 Results, Joins HDFC Bank And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
- NewsAvi Kapoor
Concentrix Reports Downbeat Q2 Earnings, Joins Nuvectis Pharma, Vishay Intertechnology And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- NewsTanya Rawat
Nuvectis Pharma Jumps 20% To 52-Week High — Here's Why NVCT Stock Is Trending
- Press releaseGlobe Newswire
Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- Press releaseBusiness Wire
Market News Alert: Nuvectis Pharma's NXP900 Demonstrates Superior Efficacy in NSCLC When Combined with Tagrisso in Cleveland Clinic Study, Following New Buy Recommendation
- Press releaseBusiness Wire
Market News Alert: Nuvectis Pharma Receives $18 Price Target and Buy Rating from Lucid Capital Markets
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- NewsAvi Kapoor
S&P 500 Moves Lower; US Crude Oil Inventories Increase
- NewsAvi Kapoor
Dow Falls Over 100 Points; US Producer Prices Rise In October
- NewsAvi Kapoor
US Stocks Edge Lower; Cisco Earnings Top Views
- Press releaseBusiness Wire
PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update
- Press releaseBusiness Wire
PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.